All questions
Specific populations: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
3 questions · 3 sources
Specific populations questions that apply to every indication of Kisqali are on Kisqali (ribociclib), all indications: Specific populations.
Specific populations
How does Kisqali safety compare in older patients with metastatic breast cancer?
Applies to Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7
Note: The discontinuation rates by age are from an exploratory, pooled, post hoc analysis of first-line patients in MONALEESA-2, MONALEESA-3, and MONALEESA-7 on the data across age groups page of the Kisqali HCP site.
Can men with metastatic breast cancer take Kisqali?
Applies to Men with HR-positive, HER2-negative advanced or metastatic breast cancer
Note: COMPLEEMENT-1 was a single-arm study; the Prescribing Information reports its overall response rate and duration of response in a table.
What is the Kisqali dose for liver (hepatic) impairment?